piperacillin (pipracil) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Piperacillin is a semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic which exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. Piperacillin sodium salt is used in combination with the β-lactamase inhibitor tazobactam sodium (ZOSYN®) for the treatment of patients with moderate to severe infections caused by susceptible bacteria.   NCATS

Chemistry

  • SMILES: CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H]2SC(C)(C)[C@@H]3C(=O)O)c2ccccc2)C(=O)C1=O
  • InChIKey: IVBHGBMCVLDMKU-GXNBUGAJSA-N
  • Mol. Mass: 517.56
  • ALogP: -0.24
  • ChEMBL Molecules:
    piperacillin  
    piperacillin sodium  
More Chemistry

Pharmacology

Combination drugs

( piperacillin (pipracil), tazobactam (Zosyn) - other name: piperacillin and tazobactam )

Alternative names

(2s,5r,6r)-6-{[(2r)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | ahp brand of pipercillin sodium - tazobactam sodium | ceftolozane - tazobactam | ceftolozane, tazobactam drug combination | cl-227193 | cl-307579 | isipen | pentacillin | piperacil | piperacilina | piperacillin | piperacillina | piperacillin anhydrous | pipéracilline | piperacillin hydrate | piperacillin sodium | piperacillin sodium salt | piperacillin - tazobactam | piperacillin-tazobactam combination product | piperacillin, tazobactam drug combination | piperacillinum | pipercillin sodium - tazobactam sodium | pipracil | pipril | t-1220 | tazocillin | tazocin | zerbaxa | zosyn

Organizations (183)

Research & Development (164)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (77)

Approved Indications (12)


 

Appendicitis

Cellulitis

Diabetic Foot

Endometritis

Healthcare-Associated Pneumonia

Intraabdominal Infections (approved 1993)

Pelvic Infection (approved 1993)

Pelvic Inflammatory Disease

Peritonitis

Pneumonia

Pneumonia, Bacterial (approved 1993)

Skin Diseases, Infectious (approved 1993)

Experimental Indications - Clinical Trial Phases 1-4 (70)


 

Abdominal Abscess (Phase 3)

Abscess (Phase 3)

Acne Vulgaris (Phase 3)

Acute Kidney Injury (Phase 4)

Appendicitis (Phase 4)

Asthma (Phase 4)

Bacteremia (Phase 4)

Bacterial Infections (Phase 4)

Bone Marrow Diseases (Phase 3)

Bronchiectasis (Phase 4)

Bronchitis (Phase 2/Phase 3)

Burns (Phase 4)

Carbapenems (Phase 4)

Cerebrospinal Fluid Otorrhea (Phase 1/Phase 2)

Cholecystitis, Acute (Phase 3)

Clinical Trial (Phase 4)

Communicable Diseases (Phase 4)

Critical Illness (Phase 4)

Cross Infection (Phase 2)

Cystic Fibrosis (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetic Foot (Phase 4)

Drug Resistance, Bacterial (Phase 4)

Drugs, Investigational (Phase 4)

Enterobacteriaceae Infections (Phase 4)

Escherichia coli Infections (Phase 4)

Febrile Neutropenia (Phase 4)

Fever (Phase 4)

Fractures, Open (Phase 4)

Graft vs Host Disease (Phase 2)

Gram-Negative Bacteria (Phase 4)

Gram-Positive Bacterial Infections (Phase 4)

Healthcare-Associated Pneumonia (Phase 3)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 3)

Infections (Phase 4)

Klebsiella Infections (Phase 4)

Klebsiella pneumoniae (Phase 4)

Leukemia (Phase 3)

Liver Transplantation (Phase 3)

Lymphoma (Phase 3)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Neonatal Sepsis (Phase 4)

Neoplasms (Phase 3)

Osteomyelitis (Phase 2)

Otitis Media (Phase 1/Phase 2)

Pancreatic Diseases (Phase 3)

Pancreatic Fistula (Phase 2)

Pancreatic Neoplasms (Phase 3)

Pancreaticoduodenectomy (Phase 3)

Pharmacokinetics (Phase 1/Phase 2)

Pneumonia (Phase 4)

Pneumonia, Bacterial (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Pseudomonas aeruginosa (Phase 4)

Pseudomonas Infections (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pyelonephritis (Phase 3)

Respiratory Tract Infections (Phase 4)

Sepsis (Phase 4)

Shock, Septic (Phase 4)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Stem Cell Transplantation (Phase 4)

Surgical Wound Infection (Phase 3)

Systemic Inflammatory Response Syndrome (Phase 2)

Ulcer (Phase 3)

Urinary Tract Infections (Phase 4)

Urination Disorders (Phase 4)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 100
  • # of Trial Organizations: 164

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue